# Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) 

Source: https://onco.cc/trials/nct04895722/  
OnCo record `nct04895722` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab, Favezelimab in colorectal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). is a phase 2 interventional study registered as NCT04895722 by Merck Sharp & Dohme LLC, with 302 participants enrolled, started 2021-06-25 and due to reach its primary completion in 2025-05-21. Interventions recorded: Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830. Conditions listed: Colorectal Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT04895722
- Phase: 2
- Setting: A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 302
- Outcomes: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR): Cohort A - Pembrolizumab/Quavonlimab 45% vs Cohort A - Pembrolizumab 29.5% vs Cohort B - Pembrolizumab/Quavonlimab 46.2% vs Cohort B - Pembrolizumab Plus MK-4830 65% vs Cohort B - Pembrolizumab/Favezelimab 37.5% vs Cohort B - Pembrolizumab/Vibostolimab 48.8% vs Cohort B - Pembrolizumab 41.5%; Overall Survival (OS): Cohort A - Pembrolizumab/Quavonlimab vs Cohort A - Pembrolizumab 37.1 months vs Cohort B - Pembrolizumab/Quavonlimab vs Cohort B - Pembrolizumab Plus MK-4830 vs Cohort B - Pembrolizumab/Favezelimab vs Cohort B - Pembrolizumab/Vibostolimab vs Cohort B - Pembrolizumab

## Sources

- ClinicalTrials.gov NCT04895722: https://clinicaltrials.gov/study/NCT04895722

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Favezelimab](https://onco.cc/drugs/favezelimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04895722.json